Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized Controlled, Single-center, Phase III Clinical Study of TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer

NCT05220020 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05220020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05220020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized Controlled, Single-center, Phase III Clinical Study of TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Unknown status
Start date
May 18, 2022
Completion date
February 28, 2025
Enrollment
299 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma